Moderna to Invest in New Science Center in Cambridge, MA
September 30 2021 - 8:07AM
Business Wire
462,000 square foot state-of-the-art building
targeting LEED Zero certification and designed to be the most
sustainable commercial lab building in Cambridge
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering
messenger RNA (mRNA) therapeutics and vaccines, today announced it
is investing in a new science center, known as the Moderna Science
Center, at 325 Binney Street in Cambridge, Massachusetts to create
a purpose-built space to support the Company’s next chapter of
discovery.
“We have been located in Massachusetts since our founding more
than 10 years ago and are proud to be based here. As we advance our
mRNA platform and science, our new science center will integrate
digital-first scientific research and development labs along with
space for innovation and co-creation with our people and our
partners around the world,” said Stéphane Bancel, Chief Executive
Officer of Moderna. “Our commitment to sustainability and
accessibility requires us to think differently about space. Even as
we grow, we are committed to minimizing our environmental
footprint. We will continue to invest in the local economy, work
with state and community partners, and leverage the incredible
innovation to attract and grow the best talent from the
Massachusetts life sciences sector as we work to deliver on the
promise of mRNA science.”
The environmentally sustainable, digitally enabled 462,000
square foot Moderna Science Center is being built to support
Moderna’s growth as the Company continues to advance its pipeline
of mRNA medicines. The new site will include custom spaces for
leading-edge research and development. The building will integrate
scientific and non-scientific spaces to maximize collaboration and
provoke disruptive innovation. Construction at the location has
begun and the Company expects to begin a phased move-in process in
2023.
Moderna has selected long-time partner Alexandria Real Estate
Equities, Inc. (NYSE: ARE), a leading creator of life science real
estate cluster ecosystems, to develop, construct and operate its
new headquarters on the Alexandria Center® at One Kendall
Square campus. Jones Lang LaSalle Incorporated (NYSE: JLL), a
global commercial real estate services company, represented Moderna
in the search for its sustainable, innovative science center.
As part of Moderna’s commitment to sustainability, the
high-performance building is targeting LEED Platinum Core &
Shell and LEED Zero Energy certifications and is designed to be the
most sustainable commercial lab building in Cambridge. To achieve
this, the building will include ultra-efficient systems and
acoustical and light pollution mitigation measures.
Since its founding in 2010, Moderna has been based in the East
Cambridge life sciences hub in Massachusetts. The Company opened
its manufacturing facility in Norwood, Massachusetts in 2018 and
recently announced an investment and expansion in Norwood,
including a more than doubling of space to transform the facility
from a production and lab space to an industrial technology center.
Today, Moderna has 37 programs in development, including 22 in
ongoing clinical studies.
Moderna was recently named number one on Fast Company’s 2021
Best Workplaces for Innovators list and number three on the
Axios/Harris 2021 Poll of Corporate Reputation Rankings.
Additionally, in 2021, Moderna was ranked number one on Fast
Company’s list of the world’s most innovative companies and was
also named to TIME’s inaugural list of the TIME100 Most Influential
Companies. In 2020, Moderna was included in Science Magazine’s list
of top employers for the sixth year in a row.
About Moderna
In 10 years since its inception, Moderna has transformed from a
science research-stage company advancing programs in the field of
messenger RNA (mRNA), to an enterprise with a diverse clinical
portfolio of vaccines and therapeutics across six modalities, a
broad intellectual property portfolio in areas including mRNA and
lipid nanoparticle formulation, and an integrated manufacturing
plant that allows for both clinical and commercial production at
scale and at unprecedented speed. Moderna maintains alliances with
a broad range of domestic and overseas government and commercial
collaborators, which has allowed for the pursuit of both
groundbreaking science and rapid scaling of manufacturing. Most
recently, Moderna’s capabilities have come together to allow the
authorized use of one of the earliest and most-effective vaccines
against the COVID-19 pandemic.
Moderna’s mRNA platform builds on continuous advances in basic
and applied mRNA science, delivery technology and manufacturing,
and has allowed the development of therapeutics and vaccines for
infectious diseases, immuno-oncology, rare diseases, cardiovascular
diseases and autoimmune diseases. Moderna has been named a top
biopharmaceutical employer by Science for the past six years. To
learn more, visit www.modernatx.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including regarding: the Company’s investment in
a new science center and the features of that facility, including
its environmental footprint. The forward-looking statements in this
press release are neither promises nor guarantees, and you should
not place undue reliance on these forward-looking statements
because they involve known and unknown risks, uncertainties, and
other factors, many of which are beyond Moderna’s control and which
could cause actual results to differ materially from those
expressed or implied by these forward-looking statements. These
risks, uncertainties, and other factors include those other risks
and uncertainties described under the heading “Risk Factors” in
Moderna’s most recent Annual Report on Form 10-K filed with the
U.S. Securities and Exchange Commission (SEC) and in subsequent
filings made by Moderna with the SEC, which are available on the
SEC’s website at www.sec.gov. Except as required by law, Moderna
disclaims any intention or responsibility for updating or revising
any forward-looking statements contained in this press release in
the event of new information, future developments or otherwise.
These forward-looking statements are based on Moderna’s current
expectations and speak only as of the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210930005549/en/
Moderna Contacts Media: Colleen Hussey Director,
Corporate Communications 617-335-1374 Colleen.Hussey@modernatx.com
Investors: Lavina Talukdar Senior Vice President & Head
of Investor Relations 617-209-5834
Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024